Navigation Links
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
Date:11/15/2007

rtunity to have face-to-face dialogues with top policymakers and executives. The Summit is aimed at industry executives in all areas of responsibility who want to create successful strategies for dealing with FDA and CMS. Attendees will get practical, real-life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles, and will also be able to benchmark their regulatory strategy against all other pharmaceutical and biotechnology companies.

Among the panels and participants scheduled for the Summit are:

- Did FDA Kill the Blockbuster? The Impact of FDA Changes on Research

and Development

-- Pfizer President, Global R&D Martin Mackay

-- Bristol-Myers Squibb SVP R&D Brian Daniels

-- Novartis SVP Global Clinical Development & Medical Affairs Glenn

Gormley

- Personalized Medicine: How Industry and Government can Make it Happen

-- Hoffmann La-Roche Inc. CEO George Abercrombie

- FDAAA and the New Active Surveillance System: What Does Data Mining

Mean for the Pharmaceutical Industry?

-- Engelberg Center for Health Care Reform Director, Former CMS

Administrator & FDA Commissioner Mark McClellan

-- FDA Assistant Commissioner for Policy Jeffrey Shuren

-- i3 Drug Safety SVP Alec Walker

- Paying for Innovation: CMS' Approach to Coverage

-- CMS Coverage & Analysis Group Director Steve Phurrough

- How the Government and Payors will Impact the Rx Market

-- CMS Center for Beneficiary Choices Chief Medical Officer Jeffrey

Kelman;

-- Former CMS Senior Advisor Larry Kocot;

-- Former Wellpoint Chief Pharmacy Officer and Founder of Doc Rock

Presents Robert Seidman

- Pharma in the Crosshairs: What are the Boundaries for Acceptable

Marketing?

-- First Assistant US Attorney, Boston Michael Loucks

-- Sidley
'/>"/>

SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
9. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... (NYSE: SGP ) today announced that the ... review status to the company,s,New Drug Application (NDA) ... reverse the effects of certain,muscle relaxants, marketed in ... bromide. Muscle relaxants are used as part of,general ...
... The following statement was issued,today by the law firm of ... given that a class action lawsuit was filed in the,United ... on,behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: ... through June 13, 2007,inclusive (the "Class Period")., If you ...
... Dec. 31 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... 30, 2007. Pharmasset reported a net loss attributable ... share, as compared to a net loss,attributable to ...
Cached Biology Technology:Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... examples of how wildlife loss leads to conflict among ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis ... for an interdisciplinary approach to tackle global biodiversity decline. ... 15% of the world,s people and provides protein for ... should come as no surprise that today,s unprecedented loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... identified several proteins in mice that might act as ... first step to finding a more reliable way to ... and teenagers use illegally to boost muscle and reduce ... in San Francisco today, scientists John Kopchick and Juan ...
... For those patients who receive the nearly 40 ... deficiency, a new oral option may soon exist. ... B12 deficiency can lead to a wide spectrum of ... Vitamin B12 deficiency is a significant health issue. Nearly ...
... ADHD-associated version of the human gene DRD4 is linked ... malnourishment in their settled cousins, according to new research ... University of Wisconsin-Milwaukee (UWM). A study by UWM ... Boston University and UNLV shows that a particular version ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections 2Did the gene for ADHD help our nomadic ancestors? 2
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... to test the crossreactivity of an antibody ... commonly used as blocking reagents or antigen ... different protein preparations on a nitrocellulose membrane. ... specificity, QC of purified antibodies, selection of ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... can provide custom microplate coating using advanced automated high throughput ... plate formats. We can also accommodate virtually any lot size ... L):, , 8 and ... microplate, 384 well microplate, ...
Biology Products: